Researchers developed a nanotechnology-based treatment for non-small cell lung cancer, according to a study conducted on April 11, 2018.
Non-small cell lung cancer is one of the most common type of lung cancer and until now, the treatment for this cancer was difficult. This new treatment method was developed by the researchers at Jefferson College of Pharmacy. The trials conducted by them in mouse models were found to be effective. A molecule that could stop growth of tumor was delivered by the nanoparticles. Also, this might make the tumors more susceptible to chemotherapy. The microRNA 29b molecule would be ineffective if it is delivered by injection alone, as it quickly degrades in the bloodstream.
As a solution to this limitation, researchers developed a nanoparticle comprised of four parts. The first one was part of a human antibody called as immunoglobulin G (IgG), to cloak the particle from the immune system. The second part was the MUC1 antigen, which acts like a navigation system guiding the nanoparticles to the MUC1-covered lung tumors. Finally, microRNA-29b molecule along with other two components are glued together using poloxamer-188, which is a sticky polymer. Further, researchers showed the capability of this spherical nanoparticle in finding the lung tumor and shrinking it in the mouse models.
Sunday Shoyele, PhD, associate professor in the Department of Pharmaceutical Sciences at Jefferson said, “This work extends our previous work demonstrating that these particles were effective in shrinking tumor tissue in a petri dish. Here we show that they are also effective in a more complex living system.” More tests have to be carried out before it can be tested on humans. Dr. Shoyele is planning to continue the research with comprehensive toxicity tests and scaling the nanoparticle manufacturing process for clinical trials.